<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>anti‐DKK1</scp> therapeutic <scp>DKN</scp> ‐01Edward J. Jarman, Luke Boulter, Stephanie MacMaster et al.|Liver International|2022Cited by 20